CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 01, 2017
Source ID
10.1016/j.exger.2017.01.025

Entities

People

  • Carlos Cruchaga
  • David W Fardo
  • John S.k. Kauwe
  • Oscar Harari
  • Peter T. Nelson
  • Yuetiva Deming
  • Yuriko Katsumata

Organizations

  • AbbVie
  • Alzheimer's Association
  • Alzheimer's Disease Neuroimaging Initiative
  • Alzheimer's Drug Discovery Foundation
  • BioClinica
  • Biogen
  • Bristol-Myers Squibb
  • Canadian Institutes of Health Research
  • Chiron Corporation
  • Dana Foundation
  • Eisai
  • Eli Lilly and Company
  • GE HealthCare
  • Innogenetics
  • Johnson & Johnson Pharmaceutical Research and Development
  • Laboratoires Servier
  • Lundbeck
  • Merck & Co.
  • Meso Scale Diagnostics (United States)
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute on Aging
  • National Institutes of Health
  • Pfizer
  • Roche (United States)
  • Takeda Pharmaceutical Company
  • United States Department of Defense